Identification

Name
Rapacuronium
Accession Number
DB04834
Type
Small Molecule
Groups
Withdrawn
Description

Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Rapacuronium bromide65Q4QDG4KC156137-99-4LVQTUXZKLGXYIU-GWSNJHLMSA-M
International/Other Brands
Raplon
Categories
UNII
GG1LBM463S
CAS number
465499-11-0
Weight
Average: 597.904
Monoisotopic: 597.462584872
Chemical Formula
C37H61N2O4
InChI Key
HTIKWNNIPGXLGM-YLINKJIISA-N
InChI
InChI=1S/C37H61N2O4/c1-6-20-39(21-12-9-13-22-39)32-24-30-28-15-14-27-23-33(42-26(3)40)31(38-18-10-8-11-19-38)25-37(27,5)29(28)16-17-36(30,4)35(32)43-34(41)7-2/h6,27-33,35H,1,7-25H2,2-5H3/q+1/t27-,28+,29-,30-,31-,32-,33-,35-,36-,37-/m0/s1
IUPAC Name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5-(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)-14-(propanoyloxy)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-13-yl]-1-(prop-2-en-1-yl)piperidin-1-ium
SMILES
[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1

Pharmacology

Indication

Used in anaesthesia, to aid and enable endotracheal intubation.

Pharmacodynamics

Rapacuronium is a rapidly acting, non-depolarizing neuromuscular blocker.

Mechanism of action
TargetActionsOrganism
AMuscarinic acetylcholine receptor M2
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

Variable. Plasma protein binding of rapacuronium was studied in vitro for human plasma by equilibrium dialysis. The protein binding was variable and ranged between 50% and 88%, which was at least partly due to hydrolysis of rapacuronium bromide to its 3-hydroxy metabolite. The specific plasma protein to which rapacuronium binds is unknown. Plasma protein binding of the 3-hydroxy metabolite was not determined.

Metabolism

Hydrolyzed to active metabolites (Cytochrome P450 system is not involved).

Route of elimination
Not Available
Half life

141 minutes (mean)

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may decrease the neuromuscular blocking activities of Rapacuronium.Experimental
16-BromoepiandrosteroneRapacuronium may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneRapacuronium may increase the adverse neuromuscular activities of 19-norandrostenedione.Experimental, Illicit
5-androstenedioneRapacuronium may increase the adverse neuromuscular activities of 5-androstenedione.Experimental, Illicit
AcetyldigitoxinRapacuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinRapacuronium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineAgmatine may increase the neuromuscular blocking activities of Rapacuronium.Experimental, Investigational
AlclometasoneRapacuronium may increase the adverse neuromuscular activities of Alclometasone.Approved
AldosteroneRapacuronium may increase the adverse neuromuscular activities of Aldosterone.Experimental, Investigational
AmbenoniumAmbenonium may decrease the neuromuscular blocking activities of Rapacuronium.Approved
AmcinonideRapacuronium may increase the adverse neuromuscular activities of Amcinonide.Approved
AmikacinThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneAmiodarone may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
AndrostenedioneRapacuronium may increase the adverse neuromuscular activities of Androstenedione.Experimental, Illicit
AnecortaveRapacuronium may increase the adverse neuromuscular activities of Anecortave.Investigational
anecortave acetateRapacuronium may increase the adverse neuromuscular activities of anecortave acetate.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Rapacuronium.Experimental, Vet Approved
AranidipineAranidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
ArbekacinArbekacin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
AtamestaneRapacuronium may increase the adverse neuromuscular activities of Atamestane.Investigational
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Rapacuronium.Approved, Vet Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
AzosemideAzosemide may decrease the neuromuscular blocking activities of Rapacuronium.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
Beclomethasone dipropionateThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Rapacuronium.Experimental
BencyclaneBencyclane may increase the neuromuscular blocking activities of Rapacuronium.Experimental
BenidipineBenidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Rapacuronium.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Rapacuronium.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Rapacuronium.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Rapacuronium.Approved, Withdrawn
BetamethasoneRapacuronium may increase the adverse neuromuscular activities of Betamethasone.Approved, Vet Approved
BioallethrinBioallethrin may increase the neuromuscular blocking activities of Rapacuronium.Approved, Experimental
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Rapacuronium.Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
Botulinum Toxin Type BRapacuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Rapacuronium.Approved
BudesonideThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Rapacuronium.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Rapacuronium.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Rapacuronium.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Rapacuronium.Approved, Investigational
CarboxyamidotriazoleCarboxyamidotriazole may increase the neuromuscular blocking activities of Rapacuronium.Investigational
CaroverineCaroverine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Rapacuronium.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rapacuronium.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the neuromuscular blocking activities of Rapacuronium.Approved
CiclesonideRapacuronium may increase the adverse neuromuscular activities of Ciclesonide.Approved, Investigational
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Rapacuronium.Approved, Investigational
ClevidipineClevidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
ClindamycinThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Clindamycin.Approved, Vet Approved
ClobetasolRapacuronium may increase the adverse neuromuscular activities of Clobetasol.Approved, Investigational
Clobetasol propionateRapacuronium may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
ClobetasoneRapacuronium may increase the adverse neuromuscular activities of Clobetasone.Approved
ClocortoloneRapacuronium may increase the adverse neuromuscular activities of Clocortolone.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Rapacuronium.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
Cortexolone 17α-propionateRapacuronium may increase the adverse neuromuscular activities of Cortexolone 17α-propionate.Investigational
CorticosteroneRapacuronium may increase the adverse neuromuscular activities of Corticosterone.Experimental
Cortisone acetateRapacuronium may increase the adverse neuromuscular activities of Cortisone acetate.Approved, Investigational
CoumaphosCoumaphos may decrease the neuromuscular blocking activities of Rapacuronium.Vet Approved
CyclandelateCyclandelate may increase the neuromuscular blocking activities of Rapacuronium.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Rapacuronium.Approved
CyclosporineThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CymarinRapacuronium may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineDarodipine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
DecamethoniumDecamethonium may decrease the neuromuscular blocking activities of Rapacuronium.Approved
DeflazacortRapacuronium may increase the adverse neuromuscular activities of Deflazacort.Approved, Investigational
DemecariumDemecarium may decrease the neuromuscular blocking activities of Rapacuronium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Rapacuronium.Approved
DesfluraneDesflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved
DeslanosideRapacuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesonideRapacuronium may increase the adverse neuromuscular activities of Desonide.Approved, Investigational
DesoximetasoneRapacuronium may increase the adverse neuromuscular activities of Desoximetasone.Approved
Desoxycorticosterone acetateRapacuronium may increase the adverse neuromuscular activities of Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateRapacuronium may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Desvenlafaxine.Approved, Investigational
DexamethasoneThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateRapacuronium may increase the adverse neuromuscular activities of Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rapacuronium.Approved
DexniguldipineDexniguldipine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Rapacuronium.Approved
DexverapamilDexverapamil may increase the neuromuscular blocking activities of Rapacuronium.Experimental
DibekacinDibekacin may increase the respiratory depressant activities of Rapacuronium.Experimental
DichlorvosDichlorvos may decrease the neuromuscular blocking activities of Rapacuronium.Vet Approved
Diethyl etherDiethyl ether may increase the neuromuscular blocking activities of Rapacuronium.Experimental
DiflorasoneRapacuronium may increase the adverse neuromuscular activities of Diflorasone.Approved
DifluocortoloneRapacuronium may increase the adverse neuromuscular activities of Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateRapacuronium may increase the adverse neuromuscular activities of Difluprednate.Approved
DigitoxinRapacuronium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinRapacuronium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Rapacuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Rapacuronium.Investigational, Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Rapacuronium.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Rapacuronium.Approved, Investigational
DipivefrinDipivefrin may decrease the neuromuscular blocking activities of Rapacuronium.Approved
DistigmineDistigmine may decrease the neuromuscular blocking activities of Rapacuronium.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Rapacuronium.Approved
DonepezilDonepezil may decrease the neuromuscular blocking activities of Rapacuronium.Approved
DotarizineDotarizine may increase the neuromuscular blocking activities of Rapacuronium.Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium.Approved, Vet Approved
EchothiophateEchothiophate may decrease the neuromuscular blocking activities of Rapacuronium.Approved
EdrophoniumEdrophonium may decrease the neuromuscular blocking activities of Rapacuronium.Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
EmopamilEmopamil may increase the neuromuscular blocking activities of Rapacuronium.Experimental
EnfluraneEnflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Vet Approved
EperisoneEperisone may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
EquileninRapacuronium may increase the adverse neuromuscular activities of Equilenin.Experimental
EquilinRapacuronium may increase the adverse neuromuscular activities of Equilin.Approved
EstroneRapacuronium may increase the adverse neuromuscular activities of Estrone.Approved
Estrone sulfateRapacuronium may increase the adverse neuromuscular activities of Estrone sulfate.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
EthanolRapacuronium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideEthosuximide may increase the neuromuscular blocking activities of Rapacuronium.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Rapacuronium.Approved
FelodipineFelodipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rapacuronium.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may decrease the neuromuscular blocking activities of Rapacuronium.Vet Approved
Fish oilFish oil may increase the neuromuscular blocking activities of Rapacuronium.Approved, Nutraceutical
FluasteroneRapacuronium may increase the adverse neuromuscular activities of Fluasterone.Investigational
FludrocortisoneRapacuronium may increase the adverse neuromuscular activities of Fludrocortisone.Approved, Investigational
FlumethasoneRapacuronium may increase the adverse neuromuscular activities of Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Rapacuronium.Approved
FlunisolideRapacuronium may increase the adverse neuromuscular activities of Flunisolide.Approved, Investigational
Fluocinolone AcetonideRapacuronium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideRapacuronium may increase the adverse neuromuscular activities of Fluocinonide.Approved, Investigational
FluocortoloneRapacuronium may increase the adverse neuromuscular activities of Fluocortolone.Approved, Withdrawn
FluorometholoneRapacuronium may increase the adverse neuromuscular activities of Fluorometholone.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Fluoxetine.Approved, Vet Approved
FluprednideneRapacuronium may increase the adverse neuromuscular activities of Fluprednidene.Approved, Withdrawn
FluprednisoloneRapacuronium may increase the adverse neuromuscular activities of Fluprednisolone.Approved
FlurandrenolideRapacuronium may increase the adverse neuromuscular activities of Flurandrenolide.Approved
FluspirileneFluspirilene may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
FluticasoneRapacuronium may increase the adverse neuromuscular activities of Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateRapacuronium may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rapacuronium.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Fluvoxamine.Approved, Investigational
FormestaneRapacuronium may increase the adverse neuromuscular activities of Formestane.Approved, Investigational, Withdrawn
FosphenytoinFosphenytoin may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
FramycetinFramycetin may increase the respiratory depressant activities of Rapacuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
GalantamineGalantamine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
Gallamine TriethiodideGallamine Triethiodide may decrease the neuromuscular blocking activities of Rapacuronium.Approved
GallopamilGallopamil may increase the neuromuscular blocking activities of Rapacuronium.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Rapacuronium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Rapacuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Rapacuronium.Experimental
Ginkgo bilobaGinkgo biloba may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Nutraceutical
GitoformateRapacuronium may increase the arrhythmogenic activities of Gitoformate.Experimental
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Rapacuronium.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Rapacuronium.Approved, Investigational
HalcinonideRapacuronium may increase the adverse neuromuscular activities of Halcinonide.Approved, Investigational, Withdrawn
HalothaneHalothane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
HE3286Rapacuronium may increase the adverse neuromuscular activities of HE3286.Investigational
Huperzine AHuperzine A may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Rapacuronium.Approved, Vet Approved
HydrocodoneRapacuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium.Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Rapacuronium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Rapacuronium.Approved
IpidacrineIpidacrine may decrease the neuromuscular blocking activities of Rapacuronium.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Ipratropium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Rapacuronium.Experimental
IsofluraneIsoflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
IsoflurophateIsoflurophate may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Withdrawn
IsradipineIsradipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
IstaroximeRapacuronium may increase the adverse neuromuscular activities of Istaroxime.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Rapacuronium.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Rapacuronium.Approved
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
Lanatoside CRapacuronium may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
LevetiracetamLevetiracetam may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Rapacuronium.Approved
LidoflazineLidoflazine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
LincomycinLincomycin may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
Lithium cationLithium may increase the neuromuscular blocking activities of Rapacuronium.Experimental
LomerizineLomerizine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
LoperamideLoperamide may increase the neuromuscular blocking activities of Rapacuronium.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Rapacuronium.Approved, Investigational
LoteprednolRapacuronium may increase the adverse neuromuscular activities of Loteprednol.Approved
Magnesium carbonateThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium citrate.Approved
Magnesium hydroxideThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Rapacuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Rapacuronium.Approved
Magnesium sulfateThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium Trisilicate.Approved
MalathionMalathion may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
ManidipineManidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
ME-609Rapacuronium may increase the adverse neuromuscular activities of ME-609.Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Rapacuronium.Approved
MedrysoneRapacuronium may increase the adverse neuromuscular activities of Medrysone.Approved
MefloquineMefloquine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
MelengestrolRapacuronium may increase the adverse neuromuscular activities of Melengestrol.Vet Approved
MemantineMemantine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
MentholMenthol may increase the neuromuscular blocking activities of Rapacuronium.Approved
Methanesulfonyl FluorideMethanesulfonyl Fluoride may decrease the neuromuscular blocking activities of Rapacuronium.Investigational
MethoxyfluraneMethoxyflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Vet Approved
MethsuximideMethsuximide may increase the neuromuscular blocking activities of Rapacuronium.Approved
MethyclothiazideMethyclothiazide may decrease the neuromuscular blocking activities of Rapacuronium.Approved
MethylprednisoloneThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinRapacuronium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetoclopramideThe therapeutic efficacy of Rapacuronium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MibefradilMibefradil may increase the neuromuscular blocking activities of Rapacuronium.Investigational, Withdrawn
MicronomicinMicronomicin may increase the respiratory depressant activities of Rapacuronium.Experimental
MinaprineMinaprine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Rapacuronium.Approved, Vet Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
MometasoneRapacuronium may increase the adverse neuromuscular activities of Mometasone.Approved, Vet Approved
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Rapacuronium.Investigational
NCX 1022Rapacuronium may increase the adverse neuromuscular activities of NCX 1022.Investigational
NeamineNeamine may increase the respiratory depressant activities of Rapacuronium.Experimental
NeomycinThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Neomycin.Approved, Vet Approved
NeostigmineNeostigmine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
NicardipineNicardipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
NifedipineNifedipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
NimesulideNimesulide may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
Nitrous oxideNitrous oxide may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
NylidrinNylidrin may increase the neuromuscular blocking activities of Rapacuronium.Approved
OleandrinRapacuronium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
Oleoyl-estroneRapacuronium may increase the adverse neuromuscular activities of Oleoyl-estrone.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Rapacuronium.Approved
OtiloniumOtilonium may increase the neuromuscular blocking activities of Rapacuronium.Experimental, Investigational
OuabainRapacuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Rapacuronium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Rapacuronium.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Vet Approved
ParamethasoneRapacuronium may increase the adverse neuromuscular activities of Paramethasone.Approved
ParaoxonParaoxon may decrease the neuromuscular blocking activities of Rapacuronium.Experimental
ParomomycinThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Paroxetine.Approved, Investigational
PenfluridolPenfluridol may increase the neuromuscular blocking activities of Rapacuronium.Experimental
PeruvosideRapacuronium may increase the arrhythmogenic activities of Peruvoside.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Rapacuronium.Approved, Investigational
PhenytoinPhenytoin may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
PhysostigminePhysostigmine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
PinaveriumPinaverium may increase the neuromuscular blocking activities of Rapacuronium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Rapacuronium.Approved
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Rapacuronium.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
Polymyxin B SulfateThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Polymyxin B Sulfate.Approved, Vet Approved
Potassium ChlorideThe risk or severity of gastrointestinal ulceration can be increased when Rapacuronium is combined with Potassium Chloride.Approved, Withdrawn
PramipexoleRapacuronium may increase the sedative activities of Pramipexole.Approved, Investigational
PrasteroneRapacuronium may increase the adverse neuromuscular activities of Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateRapacuronium may increase the adverse neuromuscular activities of Prasterone sulfate.Investigational
PrednicarbateRapacuronium may increase the adverse neuromuscular activities of Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Prednisolone.Approved, Vet Approved
PrednisoneRapacuronium may increase the adverse neuromuscular activities of Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PregnenoloneRapacuronium may increase the adverse neuromuscular activities of Pregnenolone.Approved, Experimental, Investigational
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Rapacuronium.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Rapacuronium.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Rapacuronium.Approved, Investigational
ProscillaridinRapacuronium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Pseudoephedrine.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Rapacuronium.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Pyrantel.Approved, Vet Approved
PyridostigminePyridostigmine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Rapacuronium.Approved
QuinethazoneQuinethazone may decrease the neuromuscular blocking activities of Rapacuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Rapacuronium.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
RimexoloneRapacuronium may increase the adverse neuromuscular activities of Rimexolone.Approved
RivastigmineRivastigmine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Rizatriptan.Approved
RopiniroleRapacuronium may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Rapacuronium.Approved, Investigational
SeletracetamSeletracetam may increase the neuromuscular blocking activities of Rapacuronium.Investigational
SevofluraneSevoflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
SisomicinSisomicin may increase the respiratory depressant activities of Rapacuronium.Investigational
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Rapacuronium.Approved
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Rapacuronium.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Rapacuronium.Approved, Vet Approved
SumatriptanThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Sumatriptan.Approved, Investigational
TacrineTacrine may decrease the neuromuscular blocking activities of Rapacuronium.Investigational, Withdrawn
TerodilineTerodiline may increase the neuromuscular blocking activities of Rapacuronium.Experimental
TetracyclineThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Tetracycline.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the neuromuscular blocking activities of Rapacuronium.Investigational
TetrandrineTetrandrine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
TixocortolRapacuronium may increase the adverse neuromuscular activities of Tixocortol.Approved, Withdrawn
TobramycinTobramycin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
TopiramateThe risk or severity of hyperthermia and oligohydrosis can be increased when Rapacuronium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Rapacuronium.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Rapacuronium.Approved, Investigational
TranilastTranilast may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
TriamcinoloneRapacuronium may increase the adverse neuromuscular activities of Triamcinolone.Approved, Vet Approved
TrichlorfonTrichlorfon may decrease the neuromuscular blocking activities of Rapacuronium.Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the neuromuscular blocking activities of Rapacuronium.Approved
TrimebutineTrimebutine may increase the neuromuscular blocking activities of Rapacuronium.Approved
TrimethadioneTrimethadione may increase the neuromuscular blocking activities of Rapacuronium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Rapacuronium.Approved
TubocurarineTubocurarine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
TyrothricinTyrothricin may decrease the neuromuscular blocking activities of Rapacuronium.Approved
UlobetasolRapacuronium may increase the adverse neuromuscular activities of Ulobetasol.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Rapacuronium.Approved, Investigational
VancomycinThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Rapacuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Rapacuronium.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Rapacuronium.Investigational
WIN 55212-2The risk or severity of Tachycardia and drowsiness can be increased when Rapacuronium is combined with WIN 55212-2.Experimental
XenonXenon may increase the neuromuscular blocking activities of Rapacuronium.Experimental
ZiconotideZiconotide may increase the neuromuscular blocking activities of Rapacuronium.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Zolmitriptan.Approved, Investigational
ZolpidemRapacuronium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5311399
PubChem Substance
46506932
ChemSpider
4470890
ChEBI
135845
ChEMBL
CHEMBL1201352
PharmGKB
PA451227
RxList
RxList Drug Page
Wikipedia
Rapacuronium

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5418226No1993-04-142013-04-14Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.64e-06 mg/mLALOGPS
logP3.79ALOGPS
logP2.32ChemAxon
logS-8.1ALOGPS
pKa (Strongest Basic)9.65ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area55.84 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity183.1 m3·mol-1ChemAxon
Polarizability72.25 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5993
Blood Brain Barrier+0.8937
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8064
P-glycoprotein inhibitor IInhibitor0.8735
P-glycoprotein inhibitor IIInhibitor0.908
Renal organic cation transporterNon-inhibitor0.7446
CYP450 2C9 substrateNon-substrate0.85
CYP450 2D6 substrateNon-substrate0.7966
CYP450 3A4 substrateSubstrate0.7018
CYP450 1A2 substrateNon-inhibitor0.7843
CYP450 2C9 inhibitorNon-inhibitor0.851
CYP450 2D6 inhibitorNon-inhibitor0.8561
CYP450 2C19 inhibitorNon-inhibitor0.7692
CYP450 3A4 inhibitorNon-inhibitor0.6044
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7403
Ames testNon AMES toxic0.6904
CarcinogenicityNon-carcinogens0.8664
BiodegradationNot ready biodegradable0.9886
Rat acute toxicity2.6637 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8796
hERG inhibition (predictor II)Non-inhibitor0.7349
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androstane steroids / Piperidines / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts
show 4 more
Substituents
Steroid ester / Androstane-skeleton / Dicarboxylic acid or derivatives / Piperidine / Quaternary ammonium salt / Tetraalkylammonium salt / Amino acid or derivatives / Carboxylic acid ester / Tertiary amine / Tertiary aliphatic amine
show 15 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Jooste E, Klafter F, Hirshman CA, Emala CW: A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism. Anesthesiology. 2003 Apr;98(4):906-11. [PubMed:12657852]

Drug created on September 11, 2007 15:43 / Updated on August 02, 2018 07:40